Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
INTRODUCTION CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eligibility criteria allowed enrollment of patients with poor prognostic features of advanced age or diminished Eastern Cooperative Oncology Group performance status (ECOG PS), which are typically underrepresented in or excluded from randomized controlled trials. METHODS Patients with stage IIIB/IV NSCLC and an ECOG PS of 0-2 with disease progression after ≥1 systemic therapy received nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was the incidence of grade 3-5 treatment-related select adverse events (AEs). RESULTS Among 1426 treated patients, 556 (39%) were aged ≥70 years and 128 (9%) had an ECOG PS of 2. Median treatment duration was 3.2 months. Across subgroups and the overall population, incidences of grade 3-5 treatment-related select AEs (6-9%) and grade 3-4 treatment-related AEs (TRAEs; 12-14%) were similar. One grade 5 TRAE was documented. Median overall survival (OS) was comparable in the overall population (9.1 months) and patients aged ≥70 years (10.3 months), but lower in patients with an ECOG PS of 2 (4.0 months). Patient-reported outcomes generally improved. CONCLUSIONS Data from this large predominantly community-based study, which included patients aged ≥70 years and with an ECOG PS of 2, are consistent with registrational studies. As expected, the median OS for patients with an ECOG PS of 2 was lower than for the overall population, but comparable with historical data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citation
Cited by
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Metadata
- Authors
- Spigel, D. R., McCleod, M., Jotte, R. M., Einhorn, L., Horn, L., Waterhouse, D. M., Creelan, B., Babu, S., Leighl, N. B., Chandler, J. C., Couture, F., Keogh, G., Goss, G., Daniel, D. B., Garon, E. B., Schwartzberg, L. S., Sen, R., Korytowsky, B., Li, A., Aanur, N., & Hussein, M. A.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 14
- Issue
- 9
- Pages
- 1628-1639
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2946456966
- Cited by
- 185
- References
- 2
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). https://app.cochat.ai/papers/10.1016/j.jtho.2019.05.010
- The paper
- Spigel, D. R., McCleod, M., Jotte, R. M., Einhorn, L., Horn, L., Waterhouse, D. M., Creelan, B., Babu, S., Leighl, N. B., Chandler, J. C., Couture, F., Keogh, G., Goss, G., Daniel, D. B., Garon, E. B., Schwartzberg, L. S., Sen, R., Korytowsky, B., Li, A., . . . Hussein, M. A. (2019). Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.05.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.